Skip to content
Search

Latest Stories

GPhC launches consultation on remote hearings

The General Pharmaceutical Council (GPhC) has launched a consultation on whether people agree or disagree that its hearings should continue to be held remotely when it is fair and practical to do so.

The 12-week consultation -- which ends on February 8 -- seeks views on a proposed permanent change to the GPhC’s procedural rules which will allow it to conduct hearings and meetings by teleconference or videolink.


The pharmacy regulator is seeking changes to enable it to continue to hold some hearings remotely in the future following positive feedback from those taking part in hearings during the Covid-19 pandemic which the GPhC held remotely by videolink.

"In cases where the GPhC investigates a concern about a pharmacist or pharmacy technician and decides there is evidence to show that their fitness to practise may be impaired, the case may need to be referred for a hearing before a committee," GPhC said in a statement today (November 16).

GPhC chief executive Duncan Rudkin said: “The success of remote hearings during the Covid-19 lockdown periods has demonstrated to us that remote hearings should also be an option beyond the pandemic.

"At this stage we are open-minded about the extent to which remote hearings may be used and it is important to us to ensure that any changes to our legal framework are compatible with our core values of equality, diversity and inclusion. We welcome views to help inform our next steps and guide our long-term approach to remote hearings.”

The consultation is seeking views on the positive and negative impacts of continuing to hold some hearings remotely on patients and the public, pharmacy professionals and individuals or groups sharing protected characteristics.

Views are also being sought on the advantages and disadvantages of holding remote hearings and on any circumstances when a hearing should not be held remotely.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less